Literature DB >> 21697494

Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response.

Eryu Wang1, Dal Young Kim, Scott C Weaver, Ilya Frolov.   

Abstract

Chikungunya virus (CHIKV) is an important pathogen causing outbreaks of highly debilitating and often chronic, arthralgic human disease. We have designed chimeric alphaviruses encoding CHIKV-specific structural proteins but no structural or nonstructural proteins capable of interfering with development of cellular antiviral response. These chimeras demonstrate a highly attenuated phenotype in both immunocompetent and immunocompromised (A129) mice. However, after a single vaccination, they induced protective immune response against subsequent CHIKV challenge, characterized by high titers of neutralizing antibodies. The rational design of alphavirus genomes provides a strong basis for the development of new recombinant alphaviruses with irreversible, highly attenuated, cell type-restricted phenotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697494      PMCID: PMC3165793          DOI: 10.1128/JVI.00844-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Infectious diseases. Massive outbreak draws fresh attention to little-known virus.

Authors:  Martin Enserink
Journal:  Science       Date:  2006-02-24       Impact factor: 47.728

2.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Authors:  R Edelman; C O Tacket; S S Wasserman; S A Bodison; J G Perry; J A Mangiafico
Journal:  Am J Trop Med Hyg       Date:  2000-06       Impact factor: 2.345

3.  Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.

Authors:  Dal Young Kim; Svetlana Atasheva; Niall J Foy; Eryu Wang; Elena I Frolova; Scott Weaver; Ilya Frolov
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  Preliminary isolation and identification of chikungunya virus from cases of dengue-like illness in Madras city.

Authors:  T R Rao; D E Carey; K M Pavri
Journal:  Indian J Med Res       Date:  1965-08       Impact factor: 2.375

5.  Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine.

Authors:  P R Pittman; R S Makuch; J A Mangiafico; T L Cannon; P H Gibbs; C J Peters
Journal:  Vaccine       Date:  1996-03       Impact factor: 3.641

6.  Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man.

Authors:  A C Alevizatos; R W McKinney; R D Feigin
Journal:  Am J Trop Med Hyg       Date:  1967-11       Impact factor: 2.345

7.  Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group.

Authors:  S C Weaver; R Salas; R Rico-Hesse; G V Ludwig; M S Oberste; J Boshell; R B Tesh
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

Review 8.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

9.  Evolution of alphaviruses in the eastern equine encephalomyelitis complex.

Authors:  S C Weaver; A Hagenbaugh; L A Bellew; L Gousset; V Mallampalli; J J Holland; T W Scott
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

10.  Emergence of a new epidemic/epizootic Venezuelan equine encephalitis virus in South America.

Authors:  R Rico-Hesse; S C Weaver; J de Siger; G Medina; R A Salas
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more
  38 in total

1.  New PARP gene with an anti-alphavirus function.

Authors:  Svetlana Atasheva; Maryna Akhrymuk; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Jesse H Erasmus; Robert L Seymour; Jason T Kaelber; Dal Y Kim; Grace Leal; Michael B Sherman; Ilya Frolov; Wah Chiu; Scott C Weaver; Farooq Nasar
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.

Authors:  Svetlana Atasheva; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

5.  Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo.

Authors:  Chetan D Meshram; Tetyana Lukash; Aaron T Phillips; Ivan Akhrymuk; Elena I Frolova; Ilya Frolov
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

Review 6.  Development of Vaccines for Chikungunya Fever.

Authors:  Jesse H Erasmus; Shannan L Rossi; Scott C Weaver
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

7.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

8.  Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.

Authors:  Ivan Akhrymuk; Tetyana Lukash; Ilya Frolov; Elena I Frolova
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 10.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.